Zejula (niraparib)

pill
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card
5/5
Patients and doctors who have ordered medicines from us have given us a 5 out of 5 star rating for our service

Enquire now
or read
We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Zejula (niraparib)

How to buy Zejula: You can order Zejula (niraparib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Tesaro
Disease Ovarian, Fallopian Tubes and Peritoneal Cancer
Indication Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Mode of Action PARP inhibitor
Approval Status FDA approved (USA)
CAS Number 1257044-40-8
HS Code 29331990
Strength 100 mg

Who is niraparib for?

Zejula (niraparib) is indicated as a maintenance treatment for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy [1].

Recommended dose

Complete information about Zejula (niraparib) dosage and administration can be found here: [1]
The standard dosage is:
  • 300 mg (3 capsules) once daily
For adverse reactions, consider interruption of treatment, dose reduction, or dose discontinuation.
Consult your treating doctor for personalised dosing.

What is niraparib and how does it work?

Zejula (niraparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor, indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy [1].
PARP enzymes, PARP-1 and PARP-2, play a role in DNA repair. Niraparib, by inhibiting these enzymes, induces death in tumour cells. Niraparib has shown efficacy in both cells with or without deficiencies in the genes involved in the repair of damaged DNA, namely the BRCA genes [1].

What is niraparib's approval status?

Zejula (niraparib) was approved by:
  • FDA (USA) on March 27, 2017 [2]
for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy [1].
The approval of Zejula (niraparib) was based on one main double-blind, placebo-controlled study (NOVA) involving 533 patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. All patients had received at least two prior platinum-containing regimens and were responding to their current platinum-based regimen (completely or partially). The patients were assigned to one of two groups depending on whether a mutation was detected in the BRCA gene. A total of 203 patients were assigned to the germline BRCA mutated (gBRCAmut) cohort, and 350 to the non-gBRCAmut cohort. The trial demonstrated a statistically significant improvement in progression-free survival (PFS) for patients on niraparib as compared with placebo in both the gBRCAmut cohort and the non-gBRCAmut cohort [1].
In the gBRCAmut cohort, the PFS for patients treated with niraparib was 4 times longer than for patients on placebo (21.0 months (95 % CI: 12.9, not reached) vs. 5.5 months (95 % CI: 3.8, 7.2). In the non-gBRCAmut cohort, the PFS for patients treated with niraparib was 2.4 times longer than for patients on placebo (9.3 months (95 % CI: 7.2, 11.2) vs. 3.9 months (95 % CI: 3.7, 5.5) [1].
Among the most common adverse reactions were blood deficiencies, palpitations, nausea, constipation, and vomiting. Bone marrow disorders, such as myelodysplastic syndrome or acute myeloid leukemia, occurred in 1.4 % of the patients receiving niraparib and in 1.1 % of patients assigned to placebo. Grade 3-4 hypertension occurred in 9 % of niraparib- treated patients compared with 2 % of patients assigned to placebo [1].
References
[1] Summary of Product Characteristics [FDA]: Zejula (niraparib), Manufacturer, Mar. 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf
[2] FDA. Approved Drugs: Niraparib (Zejula), 27/03/2017.
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm548487.htm








"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."

- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM



Share our website

Follow us


DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.